Matinas BioPharma downgraded by Piper Sandler
$MTNB
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral
Save time and jump to the most important pieces.
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today
4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer. Mr. Hoover's role will include business and corporate development, strategic planning, licensing, and alliance management. "We are excited to have Thomas join our executive leadership team in this critical role during this transformational time for our Company," commented Jerome D.
Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide. The Company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the NYSE American Company Guide. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreak
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash. The departing senior executives include Chief Medical Officer Dr. James Ferguson, Chief Business Officer Thomas Hoover and Chief Technology Of
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evaluation Additional LNC platform work in inflammation and oncology completed; Company evaluating next steps Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform del
SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
10-Q - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)